A surreal image of a DNA helix and a butterfly representing the genetic complexity of Lupus.

SLE Breakthrough: Unlocking Genetic Secrets to Combat Lupus

Lena Voss in Health & Wellness December 2025 • 5 min read.

"New research identifies key genetic variations that could revolutionize how we understand and treat systemic lupus erythematosus."

Systemic lupus erythematosus (SLE), often simply called lupus, is a chronic autoimmune disease where the body's immune system attacks its own tissues and organs. This can lead to inflammation, pain, and damage in various parts of the body, including the joints, skin, kidneys, blood cells, brain, heart, and lungs. Because lupus can affect so many different organ systems, its symptoms can vary widely from person to person, making it challenging to diagnose and manage.

While the exact cause of lupus remains unknown, it's believed to develop as a result of a combination of genetic predispositions, environmental triggers, and hormonal factors. Understanding the genetic component of lupus is crucial for developing more effective treatments and potentially even preventing the disease in those at risk. Recent research has focused on identifying specific genes and genetic variations that increase susceptibility to SLE, offering new insights into the complex mechanisms driving this condition.

A new study published in PLOS One has shed light on the role of copy number variations (CNVs) in the susceptibility to SLE. CNVs are alterations in the number of copies of specific DNA segments within a genome. These variations can affect gene expression and function, potentially contributing to disease development. This groundbreaking research identifies novel CNVs and genetic interactions in SLE patients, providing a foundation for future targeted therapies and personalized medicine approaches.

Decoding the Genetic Landscape: How CNVs Influence Lupus Risk

A surreal image of a DNA helix and a butterfly representing the genetic complexity of Lupus.

The study, conducted in an admixed Brazilian population, involved a case-control design to ascertain CNVs in SLE patients compared to healthy controls. Researchers used a Cytoscan HD array for whole-genome detection of CNVs, followed by quantitative real-time PCR and droplet digital PCR to validate their findings. This multi-step approach allowed for a comprehensive analysis of structural variations in the genomes of SLE patients.

One of the most significant findings was a synergistic effect between the FCGR3B and ADAM3A loci. The presence of deletions in both these loci significantly increased the risk of SLE compared to a deletion in only the FCGR3B locus. Further analysis revealed that duplications in these genes were more frequent in healthy subjects, suggesting that higher FCGR3B/ADAM3A gene copy numbers may be protective against the disease.

FCGR3B: Involved in immune complex clearance and neutrophil recruitment.
ADAM3A: A metalloproteinase with roles in cell signaling and adhesion.
CFHR4, CFHR5, HLA-DPB2: Genes that had previously not been connected to an increased SLE disease risk were also found to contribute.

These findings highlight the complex interplay of genes and structural variations in the development of SLE. The study identified 21 rare CNVs in SLE patients using a stringent four-step pipeline, including heterozygous deletions overlapping the CFHR4, CFHR5, and HLA-DPB2 genes, described for the first time in SLE patients. This comprehensive analysis provides new avenues for understanding the genetic underpinnings of SLE and developing targeted interventions.

The Road Ahead: Translating Genetic Discoveries into Clinical Solutions

This research marks a significant step forward in our understanding of the genetic complexity of SLE. By identifying novel CNVs and genetic interactions associated with the disease, scientists are paving the way for more targeted therapies and personalized medicine approaches. Further research is needed to validate these findings in larger and more diverse populations, as well as to elucidate the functional consequences of these genetic variations. Ultimately, these discoveries hold the promise of improving the lives of individuals affected by lupus through earlier diagnosis, more effective treatments, and potentially even preventive strategies.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What are copy number variations (CNVs), and why are they important in systemic lupus erythematosus (SLE) research?

Copy number variations (CNVs) are alterations in the number of copies of specific DNA segments within a genome. These variations can affect gene expression and function, potentially contributing to disease development. In systemic lupus erythematosus (SLE) research, identifying CNVs is crucial because they can reveal genetic factors that increase susceptibility to the disease. The study identified novel CNVs and genetic interactions in SLE patients, providing a foundation for future targeted therapies and personalized medicine approaches. Specifically, variations in genes like FCGR3B, ADAM3A, CFHR4, CFHR5, and HLA-DPB2 have been shown to influence SLE risk, which marks a significant step forward in our understanding of the genetic complexity of SLE.

How did the recent study investigate the role of genetics in systemic lupus erythematosus (SLE), and what populations were involved?

The recent study investigated the role of genetics in systemic lupus erythematosus (SLE) using a case-control design in an admixed Brazilian population. Researchers used a Cytoscan HD array for whole-genome detection of copy number variations (CNVs), followed by quantitative real-time PCR and droplet digital PCR to validate their findings. This multi-step approach allowed for a comprehensive analysis of structural variations in the genomes of SLE patients compared to healthy controls. The study focused on identifying novel CNVs and genetic interactions, particularly the synergistic effect between the FCGR3B and ADAM3A loci, and the contributions of CFHR4, CFHR5, and HLA-DPB2 genes.

What is the significance of the synergistic effect between the FCGR3B and ADAM3A loci in relation to systemic lupus erythematosus (SLE)?

The synergistic effect between the FCGR3B and ADAM3A loci is significant because the presence of deletions in both these loci significantly increases the risk of systemic lupus erythematosus (SLE) compared to a deletion in only the FCGR3B locus. Duplications in these genes were more frequent in healthy subjects, suggesting that higher FCGR3B/ADAM3A gene copy numbers may be protective against the disease. FCGR3B is involved in immune complex clearance and neutrophil recruitment, while ADAM3A is a metalloproteinase with roles in cell signaling and adhesion. Understanding this interaction can lead to more targeted therapies by focusing on the combined effects of these genes on the immune system and cellular functions relevant to SLE. This novel finding may have profound implications for personalized medicine approaches.

Besides FCGR3B and ADAM3A, which other genes were found to contribute to increased SLE disease risk, and what is novel about these findings?

Besides FCGR3B and ADAM3A, the genes CFHR4, CFHR5, and HLA-DPB2 were also found to contribute to increased systemic lupus erythematosus (SLE) disease risk. What's novel is that these genes had previously not been strongly connected to an increased SLE disease risk. The study identified heterozygous deletions overlapping the CFHR4, CFHR5, and HLA-DPB2 genes in SLE patients. Discovering these previously unassociated genes provides new avenues for understanding the genetic underpinnings of SLE and developing targeted interventions, adding depth to the genetic landscape of SLE susceptibility.

How might the discoveries about copy number variations (CNVs) in systemic lupus erythematosus (SLE) influence future treatments and preventative strategies?

Discoveries about copy number variations (CNVs) in systemic lupus erythematosus (SLE) can influence future treatments and preventative strategies by paving the way for more targeted therapies and personalized medicine approaches. By identifying novel CNVs and genetic interactions associated with the disease, scientists can develop treatments that specifically address the genetic factors driving SLE in individual patients. For example, understanding the role of genes like FCGR3B, ADAM3A, CFHR4, CFHR5, and HLA-DPB2 could lead to therapies that modulate their expression or function to reduce disease risk or severity. Furthermore, genetic screening for these CNVs could help identify individuals at higher risk of developing SLE, allowing for earlier diagnosis, preventive measures, and more effective management of the disease. Further research is needed to validate these findings in larger and more diverse populations.